FDA assigned PDUFA target action date of January 29, 2027No advisory committee meeting expectedBOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- ...

The FDA has accepted the NDA for ulixacaltamide HCl, a selective T-type calcium channel inhibitor for essential tremor, following positive phase 3 Essential3 trial results.

SARASOTA, Fla. ( WWSB) - Alan Dee of Sarasota stretches out both of his hands. One is relatively still while the other shakes ...

Praxis, a top biotech stock, surged Tuesday after the FDA assigned a potential approval date for its essential tremor ...

Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device ...

Praxis Precision Medicines Inc. PRAX shares are up on Tuesday as the company announced FDA acceptance of its New Drug ...

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis ...

Cala announced today that it received FDA clearance for its kIQ Plus next-generation wearable neurostimulation device.

Katharine Hepburn had it. So did playwright Eugene O'Neill and Sen. Robert Byrd. Essential tremor is a condition that causes involuntary shaking. While it usually develops in middle age, it can start ...

Dear Doctors: I think I’m coming down with essential tremors, which run in my family. At age 81, my left hand and left leg are making movements that I’m not initiating. My dad died at 95, and because ...